Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Garima

      Articles By : Garima

      Currency headwinds quell drug gains in Q4; says Merck KGaA

      Currency headwinds quell drug gains in Q4; says Merck KGaA

      Garima10 March 2019 8:59 AM IST
      FRANKFURT: Germany's Merck KGaA posted a 1.3 per cent decline in adjusted core earnings in the fourth quarter as negative currency effects more than...
      Bombay High Court directs Nuziveedu Seeds to pay Rs 138 crore dues of Mahyco Monsanto Biotech

      Bombay High Court directs Nuziveedu Seeds to pay Rs 138 crore dues of Mahyco Monsanto Biotech

      Garima9 March 2019 9:30 AM IST
      According to a statement released by MMBL, Nuziveedu Seeds Ltd (NSL) and several other seed makers stopped payment of trait fee on the technology to...
      Bristol Myers defends Celgene bet as investor criticism grows

      Bristol Myers defends Celgene bet as investor criticism grows

      Garima9 March 2019 9:26 AM IST
      As its most important cancer immunotherapy Opdivo faces competition from Merck & Co's Keytruda, Bristol Myers is betting on Celgene to strengthen...
      GUILTY: Abbott Healthcare did not pass Rs 96.59 lakh GST benefit to consumers

      GUILTY: Abbott Healthcare did not pass Rs 96.59 lakh GST benefit to consumers

      Garima7 March 2019 11:41 AM IST
      Despite a fall in tax rates from 28% to 18%, the base price of the product of Abbott was increased from Rs 202.06 to Rs 230.90 per unit which...
      Orchid Pharma Insolvency Case: Ingen Capital CEO warned of arrest

      Orchid Pharma Insolvency Case: Ingen Capital CEO warned of arrest

      Garima4 March 2019 2:00 PM IST
      Chennai: In a major setback to Ingen capital, the National Company Law Appellate Tribunal (NCLAT) has called for a response to a show cause notice...
      Aurobindo Pharma acquires 7 oncology products worth over Rs 2100 crore from US firm

      Aurobindo Pharma acquires 7 oncology products worth over Rs 2100 crore from US firm

      Garima4 March 2019 12:19 PM IST
      In January, Aurobindo Pharma had said it will acquire a portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals Inc in a...
      Glenmark announces results from new analysis on Ryaltris

      Glenmark announces results from new analysis on Ryaltris

      Garima3 March 2019 9:15 AM IST
      Glenmark Pharmaceuticals has studied Ryaltris in seven clinical trials involving more than 4,000 patients. Results from these clinical trials of...
      Oops- Biocon chief fined Rs 9.5 lakh by Infosys

      Oops- Biocon chief fined Rs 9.5 lakh by Infosys

      Garima1 March 2019 5:51 PM IST
      In its filing, the company stated that such trade is a violation of the Company's Insider Trading Policy and the Sebi (Prohibition of Insider Trading)...
      Pharma stocks could see turbulence from US Senate drug price hearing

      Pharma stocks could see turbulence from US Senate drug price hearing

      Garima1 March 2019 9:00 AM IST
      The Senate Finance Committee hearing on drug pricing is likely to turn up the volume on the debate over healthcare costs, an issue looming as a...
      ICMR, Pfizer tie up unethical, says RSS Economic wing, demands immediate Cancellation

      ICMR, Pfizer tie up unethical, says RSS Economic wing, demands immediate Cancellation

      Garima28 Feb 2019 11:50 AM IST
      SJM urged the minister to scrap the ICMR, Pfizer collaboration on an urgent basis and investigate the circumstances that led to such "an unethical"...
      Supreme court directs former Ranbaxy promoters to appear on March 14

      Supreme court directs former Ranbaxy promoters to appear on March 14

      Garima28 Feb 2019 9:30 AM IST
      "The court would like to have the personal presence of respondent nos. 2 and 4 (Malvinder and Shivinder Singh) in SLP(C) No... along with their...
      True North to acquire controlling stake in Max Bupa Health Insurance for Rs 511 crore

      True North to acquire controlling stake in Max Bupa Health Insurance for Rs 511 crore

      Garima27 Feb 2019 12:51 PM IST
      The transaction will lead to a cash inflow of Rs 511 crore for Max India. The company intends to utilize the proceeds to invest in both existing and...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok